TrialArthritis research & therapy2022

Inhibition of bone erosion, determined by high-resolution peripheral quantitative computed tomography (HR-pQCT), in rheumatoid arthritis patients receiving a conventional synthetic disease-modifying anti-rheumatic drug (csDMARD) plus denosumab vs csDMARD therapy alone: an open-label, randomized, parallel-group study.

Naoki Iwamoto et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.